# PemCab (NCT03534804)

> Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03534804
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: University of Utah
- Conditions: Metastatic Urothelial Carcinoma; Bladder Cancer
- Interventions: Cabozantinib; Pembrolizumab
- Enrollment: 37
- Primary outcome: Count of Participants With Response Measured by RECIST 1.1

## Commentary we found

- X threads: 14
- YouTube: 3
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pemcab-nct03534804

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03534804", "email": "<work email>"}; the inbox owner confirms by the emailed link.